NO326826B3 - Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav - Google Patents

Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav Download PDF

Info

Publication number: NO326826B3
Authority: NO; Norway
Prior art keywords: compounds; formula; group; compound; amino acid
Prior art date: 1996-07-23

Application number

NO19990300A

Other languages

English (en)

Norwegian (no)

Other versions

NO326826B1 (no

NO990300D0 (no

NO990300L (no

Inventor

Maurizio Delcanale

Paolo Chiesi

Paolo Ventura

Renato De Fanti

Elisabetta Armani

Gino Viletti

Claudio Pietra

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-23

Filing date

1999-01-22

Publication date

2010-06-07

1999-01-22 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

1999-01-22 Publication of NO990300D0 publication Critical patent/NO990300D0/no

1999-01-22 Publication of NO990300L publication Critical patent/NO990300L/no

2009-02-23 Publication of NO326826B1 publication Critical patent/NO326826B1/no

2010-06-07 Publication of NO326826B3 publication Critical patent/NO326826B3/no

Links

238000002360 preparation method Methods 0.000 title description 9
150000001370 alpha-amino acid derivatives Chemical class 0.000 title description 4
235000008206 alpha-amino acids Nutrition 0.000 title description 4
230000001225 therapeutic effect Effects 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 68
230000001773 anti-convulsant effect Effects 0.000 claims description 22
-1 2-indanyl Chemical group 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 12
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 6
150000001412 amines Chemical class 0.000 claims description 5
229910021529 ammonia Inorganic materials 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
238000007112 amidation reaction Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
230000009435 amidation Effects 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
238000009833 condensation Methods 0.000 claims description 3
230000005494 condensation Effects 0.000 claims description 3
125000001188 haloalkyl group Chemical group 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
101100294102 Caenorhabditis elegans nhr-2 gene Chemical group 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
238000007126 N-alkylation reaction Methods 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
230000003287 optical effect Effects 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
238000007127 saponification reaction Methods 0.000 claims description 2
125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 3
239000000969 carrier Substances 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
230000000694 effects Effects 0.000 description 22
239000001961 anticonvulsive agent Substances 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
229960003965 antiepileptics Drugs 0.000 description 18
239000000243 solution Substances 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
238000012360 testing method Methods 0.000 description 15
241000699670 Mus sp. Species 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
241000700159 Rattus Species 0.000 description 7
239000000126 substance Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
206010010904 Convulsion Diseases 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
GJNNXIYZWIZFRH-UHFFFAOYSA-N 2-(pentylamino)acetamide Chemical compound CCCCCNCC(N)=O GJNNXIYZWIZFRH-UHFFFAOYSA-N 0.000 description 5
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010029350 Neurotoxicity Diseases 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
206010044221 Toxic encephalopathy Diseases 0.000 description 5
125000003545 alkoxy group Chemical group 0.000 description 5
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 5
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 5
230000007135 neurotoxicity Effects 0.000 description 5
231100000228 neurotoxicity Toxicity 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 5
239000000725 suspension Substances 0.000 description 5
XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
230000036461 convulsion Effects 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
229950000928 milacemide Drugs 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 3
HQMLIDZJXVVKCW-UHFFFAOYSA-N 2-aminopropanamide Chemical compound CC(N)C(N)=O HQMLIDZJXVVKCW-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
206010043994 Tonic convulsion Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
238000006268 reductive amination reaction Methods 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
229940084026 sodium valproate Drugs 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
231100000816 toxic dose Toxicity 0.000 description 3
MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
102000010909 Monoamine Oxidase Human genes 0.000 description 2
108010062431 Monoamine oxidase Proteins 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101000655609 Streptomyces azureus Thiostrepton Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000004744 fabric Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
MDDHPYSNIXNEBV-UHFFFAOYSA-N methyl 2-(2,3-dihydro-1h-inden-1-ylamino)acetate Chemical compound C1=CC=C2C(NCC(=O)OC)CCC2=C1 MDDHPYSNIXNEBV-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000007659 motor function Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000001256 tonic effect Effects 0.000 description 2
HRWCWYGWEVVDLT-GKAPJAKFSA-N (1s)-2-amino-2,3-dihydro-1h-inden-1-ol Chemical class C1=CC=C2[C@H](O)C(N)CC2=C1 HRWCWYGWEVVDLT-GKAPJAKFSA-N 0.000 description 1
QEAATADJGLPUFC-YDALLXLXSA-N (2s)-2-(2,3-dihydro-1h-inden-2-ylamino)-3-hydroxy-n-methylpropanamide;hydrochloride Chemical compound Cl.C1=CC=C2CC(N[C@@H](CO)C(=O)NC)CC2=C1 QEAATADJGLPUFC-YDALLXLXSA-N 0.000 description 1
PPDUPFQTBZWYRZ-QMMMGPOBSA-N (2s)-2-(2,3-dihydro-1h-inden-2-ylamino)propanamide Chemical compound C1=CC=C2CC(N[C@@H](C)C(N)=O)CC2=C1 PPDUPFQTBZWYRZ-QMMMGPOBSA-N 0.000 description 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
JPNNIRXUJSPGRM-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-ylamino)acetamide;hydrochloride Chemical compound Cl.C1=CC=C2CC(NCC(=O)N)CC2=C1 JPNNIRXUJSPGRM-UHFFFAOYSA-N 0.000 description 1
GSMRNRFOLLLDKK-UHFFFAOYSA-N 2-[(5,6-difluoro-2,3-dihydro-1h-inden-2-yl)amino]acetamide;hydrochloride Chemical compound Cl.FC1=C(F)C=C2CC(NCC(=O)N)CC2=C1 GSMRNRFOLLLDKK-UHFFFAOYSA-N 0.000 description 1
BBLBYLVZZRYLML-UHFFFAOYSA-N 2-[(5,6-dimethoxy-2,3-dihydro-1h-inden-2-yl)amino]acetamide Chemical compound C1=C(OC)C(OC)=CC2=C1CC(NCC(N)=O)C2 BBLBYLVZZRYLML-UHFFFAOYSA-N 0.000 description 1
YEIIYNGCRNULOA-UHFFFAOYSA-N 2-[(5-fluoro-2,3-dihydro-1h-inden-2-yl)amino]acetamide;hydrochloride Chemical compound Cl.C1=C(F)C=C2CC(NCC(=O)N)CC2=C1 YEIIYNGCRNULOA-UHFFFAOYSA-N 0.000 description 1
FTEUFBQBZNRJGQ-UHFFFAOYSA-N 2-[2,3-dihydro-1h-inden-2-yl(methyl)amino]acetamide Chemical compound C1=CC=C2CC(N(CC(N)=O)C)CC2=C1 FTEUFBQBZNRJGQ-UHFFFAOYSA-N 0.000 description 1
LXMXYMFXYWVGLB-JTQLQIEISA-N 2-[[(1s)-2,3-dihydro-1h-inden-1-yl]amino]acetamide Chemical compound C1=CC=C2[C@@H](NCC(=O)N)CCC2=C1 LXMXYMFXYWVGLB-JTQLQIEISA-N 0.000 description 1
BHGQBJPBTDBJIB-UHFFFAOYSA-N 2-aminoacetamide Chemical compound NCC(N)=O.NCC(N)=O BHGQBJPBTDBJIB-UHFFFAOYSA-N 0.000 description 1
AXBBGHFTZOZJHA-UHFFFAOYSA-N 2-hydroxyimino-5,6-dimethoxy-3h-inden-1-one Chemical compound C1=C(OC)C(OC)=CC2=C1C(=O)C(=NO)C2 AXBBGHFTZOZJHA-UHFFFAOYSA-N 0.000 description 1
DZFUCWJCVNOGJS-UHFFFAOYSA-N 3-amino-1,2,3,4-tetrahydronaphthalen-2-ol Chemical class C1=CC=C2CC(O)C(N)CC2=C1 DZFUCWJCVNOGJS-UHFFFAOYSA-N 0.000 description 1
LFBRNZOCESIFSE-UHFFFAOYSA-N 3-hydroxy-2-[[4-(3-phenylpropoxy)phenyl]methylamino]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(CNC(CO)C(=O)N)=CC=C1OCCCC1=CC=CC=C1 LFBRNZOCESIFSE-UHFFFAOYSA-N 0.000 description 1
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
TZASGTHDRXFGHT-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C(OC)C(OC)=CC2=C1CC(N)C2 TZASGTHDRXFGHT-UHFFFAOYSA-N 0.000 description 1
IHMQOBPGHZFGLC-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OC)C(OC)=CC2=C1C(=O)CC2 IHMQOBPGHZFGLC-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical class NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
206010061334 Partial seizures Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
230000002555 anti-neurodegenerative effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
230000001663 anti-spastic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
UBVVEPHNFMLDFZ-LBPRGKRZSA-N methyl (2s)-2-(2,3-dihydro-1h-inden-2-ylamino)-3-hydroxypropanoate Chemical compound C1=CC=C2CC(N[C@@H](CO)C(=O)OC)CC2=C1 UBVVEPHNFMLDFZ-LBPRGKRZSA-N 0.000 description 1
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003354 serine derivatives Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19990300A 1996-07-23 1999-01-22 Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav NO326826B3 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT96MI001544A IT1283489B1 (it)	1996-07-23	1996-07-23	Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico
PCT/EP1997/003773 WO1998003472A1 (en)	1996-07-23	1997-07-15	Alpha-amino acid amides, preparation thereof and the therapeutical use thereof

Publications (4)

Publication Number	Publication Date
NO990300D0 NO990300D0 (no)	1999-01-22
NO990300L NO990300L (no)	1999-01-22
NO326826B1 NO326826B1 (no)	2009-02-23
NO326826B3 true NO326826B3 (no)	2010-06-07

Family

ID=11374651

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990300A NO326826B3 (no)	1996-07-23	1999-01-22	Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav

Country Status (26)

Country	Link
US (1)	US6114391A (cs)
EP (1)	EP0951465B1 (cs)
JP (1)	JP4542208B2 (cs)
CN (1)	CN1211351C (cs)
AR (1)	AR007963A1 (cs)
AT (1)	ATE237584T1 (cs)
AU (1)	AU729176B2 (cs)
CA (1)	CA2261259C (cs)
CZ (1)	CZ295824B6 (cs)
DE (1)	DE69721052T2 (cs)
DK (1)	DK0951465T3 (cs)
ES (1)	ES2195158T3 (cs)
HU (1)	HU225623B1 (cs)
ID (1)	ID17999A (cs)
IL (1)	IL128020A (cs)
IT (1)	IT1283489B1 (cs)
MY (1)	MY118244A (cs)
NO (1)	NO326826B3 (cs)
NZ (1)	NZ333869A (cs)
PT (1)	PT951465E (cs)
RU (1)	RU2174511C2 (cs)
SI (1)	SI0951465T1 (cs)
TR (1)	TR199900087T2 (cs)
TW (1)	TW557291B (cs)
WO (1)	WO1998003472A1 (cs)
ZA (1)	ZA976479B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5672746A (en)	1994-08-30	1997-09-30	American Biogenetic Sciences, Inc.	Antiproliferative and neurotrophic molecules
PL345364A1 (en)	1998-06-22	2001-12-17	American Biogenetic Sciences	The use of valproic acid analog for the treatment and prevention of migraine and affective illness
US20030035784A1 (en)	2001-03-05	2003-02-20	Kao Corporation	Hair cosmetic, aminocarboxylic acid amide and method for producing the same
PT1321139E (pt) *	2001-12-21	2007-01-31	Chiesi Farma Spa	Derivados de 2-indanilamino para a terapêutica da cor crónica
FR2843590B1 (fr) *	2002-08-14	2007-10-05	Prestwick Scient Capital Inc	Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
AU2005270949B2 (en) *	2004-08-03	2011-02-03	Chiesi Farmaceutici S.P.A.	Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
US9475757B2 (en)	2013-05-03	2016-10-25	Council Of Scientific & Industrial Research	Synthesis of anti-Parkinson agent
CN105646252A (zh) *	2016-02-25	2016-06-08	吉尔生化（上海）有限公司	一种丝氨酸酰胺盐酸盐的合成方法
KR102286897B1 (ko)	2019-06-25	2021-08-09	(주)앰틱스바이오	신규한 아미노알칸산에 바이페닐기를 도입한 유도체 화합물 및 이를 포함하는 항진균성 약학적 조성물
US20240190809A1 (en) *	2021-05-11	2024-06-13	Awakn Ls Europe Holdings Limited	Therapeutic aminoindane compounds and compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3010599A1 (de) *	1979-03-22	1980-10-09	Continental Pharma	Derivate von glycinamid, deren herstellung und verwendung
DE3718317A1 (de) *	1986-12-10	1988-06-16	Bayer Ag	Substituierte basische 2-aminotetraline
NL8800260A (nl) *	1988-02-04	1989-09-01	Stamicarbon	Alpha-n-hydroxyaminozuren, amiden en andere derivaten daarvan.
EP0612751A3 (en) *	1988-03-16	1994-09-21	Eisai Co Ltd	Compounds for the preparation of cephem derivatives.
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5198547A (en) *	1992-03-16	1993-03-30	South Alabama Medical Science Foundation, Usa	Process for N5-formylating tetrahydropteridines
GB9306886D0 (en) *	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) *	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5332840A (en) *	1993-05-27	1994-07-26	Bristol-Myers Squibb Company	Method for preparing a benzaldehyde intermediate
ES2139220T3 (es) *	1994-06-28	2000-02-01	Bayer Ag	Derivados de aminoacidos y su empleo como agentes pesticidas.

1996
- 1996-07-23 IT IT96MI001544A patent/IT1283489B1/it active IP Right Grant
1997
- 1997-07-15 ES ES97933680T patent/ES2195158T3/es not_active Expired - Lifetime
- 1997-07-15 IL IL12802097A patent/IL128020A/en not_active IP Right Cessation
- 1997-07-15 AT AT97933680T patent/ATE237584T1/de not_active IP Right Cessation
- 1997-07-15 AU AU36952/97A patent/AU729176B2/en not_active Ceased
- 1997-07-15 CA CA002261259A patent/CA2261259C/en not_active Expired - Fee Related
- 1997-07-15 JP JP50542498A patent/JP4542208B2/ja not_active Expired - Fee Related
- 1997-07-15 PT PT97933680T patent/PT951465E/pt unknown
- 1997-07-15 EP EP97933680A patent/EP0951465B1/en not_active Expired - Lifetime
- 1997-07-15 DE DE69721052T patent/DE69721052T2/de not_active Expired - Lifetime
- 1997-07-15 NZ NZ333869A patent/NZ333869A/xx not_active IP Right Cessation
- 1997-07-15 US US09/147,553 patent/US6114391A/en not_active Expired - Fee Related
- 1997-07-15 CZ CZ1999182A patent/CZ295824B6/cs not_active IP Right Cessation
- 1997-07-15 DK DK97933680T patent/DK0951465T3/da active
- 1997-07-15 WO PCT/EP1997/003773 patent/WO1998003472A1/en not_active Ceased
- 1997-07-15 CN CNB971966044A patent/CN1211351C/zh not_active Expired - Fee Related
- 1997-07-15 SI SI9730515T patent/SI0951465T1/xx unknown
- 1997-07-15 RU RU99103681/04A patent/RU2174511C2/ru not_active IP Right Cessation
- 1997-07-15 TR TR1999/00087T patent/TR199900087T2/xx unknown
- 1997-07-15 HU HU9902992A patent/HU225623B1/hu not_active IP Right Cessation
- 1997-07-21 ID IDP972516A patent/ID17999A/id unknown
- 1997-07-22 AR ARP970103300A patent/AR007963A1/es active IP Right Grant
- 1997-07-22 MY MYPI97003309A patent/MY118244A/en unknown
- 1997-07-22 ZA ZA9706479A patent/ZA976479B/xx unknown
- 1997-09-10 TW TW086113174A patent/TW557291B/zh active
1999
- 1999-01-22 NO NO19990300A patent/NO326826B3/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69721052T2 (de)	2004-02-05
JP4542208B2 (ja)	2010-09-08
IL128020A (en)	2002-04-21
DK0951465T3 (da)	2003-08-11
ATE237584T1 (de)	2003-05-15
ITMI961544A1 (it)	1998-01-23
AU729176B2 (en)	2001-01-25
IT1283489B1 (it)	1998-04-21
TR199900087T2 (xx)	1999-03-22
SI0951465T1 (en)	2003-08-31
NO326826B1 (no)	2009-02-23
RU2174511C2 (ru)	2001-10-10
EP0951465A1 (en)	1999-10-27
HU225623B1 (en)	2007-05-02
US6114391A (en)	2000-09-05
CN1211351C (zh)	2005-07-20
EP0951465B1 (en)	2003-04-16
DE69721052D1 (de)	2003-05-22
NO990300D0 (no)	1999-01-22
WO1998003472A1 (en)	1998-01-29
ES2195158T3 (es)	2003-12-01
CZ18299A3 (cs)	1999-06-16
TW557291B (en)	2003-10-11
HUP9902992A3 (en)	2004-04-28
AR007963A1 (es)	1999-11-24
CA2261259C (en)	2006-10-03
CN1225625A (zh)	1999-08-11
ITMI961544A0 (cs)	1996-07-23
CA2261259A1 (en)	1998-01-29
NO990300L (no)	1999-01-22
AU3695297A (en)	1998-02-10
JP2001506577A (ja)	2001-05-22
IL128020A0 (en)	1999-11-30
MY118244A (en)	2004-09-30
CZ295824B6 (cs)	2005-11-16
ID17999A (id)	1998-02-19
NZ333869A (en)	2000-05-26
ZA976479B (en)	1998-03-02
PT951465E (pt)	2003-08-29

Legal Events

Date	Code	Title	Description
2010-06-07	LC4	Limitation of patent rights - b3 (par. 39b patent act)	Effective date: 20100607
2012-02-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6528685B2 (en)	2003-03-04	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0738149A1 (en)	1996-10-23	1-aminoindan derivatives and compositions thereof
WO1996021640A1 (en)	1996-07-18	Optically active aminoindane derivatives and preparation thereof
KR20190008411A (ko)	2019-01-23	플로오르화 2-아미노-4-(치환된 아미노)페닐 카르밤산염 유도체
JP4542208B2 (ja)	2010-09-08	α―アミノ酸アミド、その製造方法及びその治療的使用
EP0643688B1 (en)	1998-07-29	Substituted (arylalkoxybenzyl)aminopropanamide derivatives, their preparation and use as anti-epileptic, neuroprotective and antidepressant agents
JP2611816B2 (ja)	1997-05-21	Ｎ−（ヒドロキシ）アラルキルフェニルエタノールアミン類のｏ−アルキル化方法
JP3542600B2 (ja)	2004-07-14	置換（アリールアルキルアミノベンジル）アミノプロピオンアミド誘導体及びその製造方法
CA2026216C (en)	1998-12-01	Optically active benzyl alcohol compound and the use thereof
Ghidini et al.	2006	Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives
JPH0653715B2 (ja)	1994-07-20	２−アミノアセトアミド誘導体
AU2002228737B2 (en)	2007-01-04	Prodrugs of excitatory amino acids
CA2551128A1 (en)	2005-07-28	Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifiying and obtaining the polymorphs thereof
WO2004022532A1 (en)	2004-03-18	Benzenesulphonamides and process for their preparation
EP2093218A1 (en)	2009-08-26	Arylalkyl substituted imidazolidinones